Datopotamab Deruxtecan (Dato-DXd) trials for Breast cancer

All Datopotamab Deruxtecan (Dato-DXd) trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Datopotamab Deruxtecan (Dato-DXd) for Breast cancer

• An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
  NCT07357597 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 78 locations
• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
  NCT06954480 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
  NCT05417594 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 32 locations

Common questions

How many trials study Datopotamab Deruxtecan (Dato-DXd) for Breast cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.